Compare Dollar General Corp. (DG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Sanofi SA — how do they compare? Dollar General Corp. trades at $127.23 (market cap $27.42B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 3.5× Dollar General Corp.'s market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Sanofi SA for 94 Days on average.
| DG | SNY | |
|---|---|---|
Market Cap | $27.42B | $95.18B |
Volume | 2,291,517 | 2,995,646 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $52.34 |
52-Week Low | $95.94 | $39.51 |
Typical Hold Time | 59 Days | 94 Days |
Enterprise Value | $41.60B | $114.48B |
Dividend Yield | 1.9% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $127.23, up 4.15% today, showing strong momentum with three consecutive quarterly earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward movement. Fundamentally, DG maintains solid profitability with 19.69% ROE and attractive valuation metrics including P/E of 16.14 and P/S of 0.63. Recent developments include tariff refunds boosting margins and expansion of same-day delivery through Instacart partnerships.
The outlook remains positive with analyst consensus targeting $137.27, representing 7.9% upside potential. Key opportunities include margin expansion from tariff benefits and retail media network growth, while risks involve consumer spending pressure and competitive discount retail landscape. With 56% analyst buy ratings and improving cash flow trends, DG presents a compelling value proposition in the retail sector.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
